Table 1.
Demographics and clinical characteristics of study population.
| Örebro cohort | Umeå cohort | |||||
|---|---|---|---|---|---|---|
| Mild disease1 | Non-severe hypoxemia2 | Severe hypoxemia3 | Mild disease1* | Non-severe hypoxemia2 | Severe hypoxemia3 | |
| (n=12) | (n=48) | (n=31) | (n=49) | (n=19) | (n=8) | |
| Age median (IQR) | 57 (46-67) | 53 (42-69) | 59 (48-65) | 52 (45-64) | 52 (43-65) | 60 (53-64) |
| Sex male | 8 (67) | 29 (60) | 21 (68) | 25 (51) | 10 (53) | 7 (88) |
| Hospital stay days median (IQR) | 4 (2-5) | 5 (4-7) | 12 (8-19) | 2 (2-5)# | 5 (4-8)¤ | 16 (9-20)¤ |
| Days since symptom onset median (IQR)4 | 9 (8-13) | 11 (9-15) | 11 (9-13) | 7 (5-8)# | 10 (7-12) | 13 (8-17) |
| BMI median (IQR) | 29.5 (28-31) | 30 (27-34) | 33 (28.5-37) | 25 (23-28) | 31 (28-37) | 30 (27-32) |
| Active smoker | 0 | 1 (2)¤ | 0¤ | 15 (30) | 6 (32) | 4 (50) |
| Charlson comorbidity score median (IQR) | 0 (0-1) | 0 (0-1) | 0 (0-1) | 0 (0-1) | 0 (0-1) | 0 (0-1) |
| Charlson comorbidity score ≥1 | 5 (42) | 21 (44) | 11 (36) | 13 (27) | 7 (37) | 3 (38) |
| Hypertension | 6 (50) | 18 (38) | 12 (39) | 12 (25) | 8 (42) | 4 (8) |
| Heart disease | 2 (17) | 6 (13) | 3 (10) | 5 (10) | 4 (21) | 1 (13) |
| Chronic lung disease a | 3 (25) | 9 (19) | 7 (23) | 9 (18) | 5 (26) | 3 (38) |
| Diabetes | 2 (18) | 8 (17) | 3 (10) | 3 (6) | 4 (21) | 0 |
| Immunosuppression | 0 | 4 (8) | 0 | 1 (2) | 1 (5) | 0 |
| Chronic kidney disease | 0 | 2 (4) | 0 | 0 | 0 | 0 |
Data presented in table as n (%) if not further specified.
1Non-hospitalized patient, or hospitalized patient with no need of oxygen treatment.
2Conventional oxygen treatment, or high nasal flow oxygen (HFNO) treatment with FiO2 < 50%.
3HFNO with FiO2 ≥50%, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) treatment.
4at enrollment.
*Proportion of mild cases that was hospitalised 8/49 (16%).
a
asthma, chronic obstructive pulmonary disease, pulmonal hypertension, lung fibrosis, or tuberculosis.
¤1 patient with missing data.
#2 patients with missing data.